LIfT BioSciences, a pre-clinical stage company moving into first-in-human trials with an allogeneic neutrophil progenitor based cell therapy, and Minaris Regenerative Medicine GmbH, a global contract development and manufacturing organization (CDMO) provider for the cell and gene therapy industry, have formed a partnership for N-LIfT, LIfT’s first-in-class neutrophil progenitor based leukocyte infusion therapy for the treatment of various cancer indications, including pancreatic cancer, lung cancer and other solid tumors.